Pigment Cell & Melanoma Research最新文献

The human red hair color (RHC) trait is caused by increased pheomelanin (red-yellow) and reduced eumelanin (black-brown) pigment in skin and hair due to diminished melanocortin 1 receptor (MC1R) function. In addition, individuals harboring the RHC trait are predisposed to melanoma development. While MC1R variants have been established as causative of RHC and are a well-defined risk factor for melanoma, it remains unclear mechanistically why decreased MC1R signaling alters pigmentation and increases melanoma susceptibility. Here, we use single-cell RNA sequencing (scRNA-seq) of melanocytes isolated from RHC mouse models to define a MC1R-inhibited Gene Signature (MiGS) comprising a large set of previously unidentified genes which may be implicated in melanogenesis and oncogenic transformation. We show that one of the candidate MiGS genes, TBX3, a well-known anti-senescence transcription factor implicated in melanoma progression, binds both E-box and T-box elements to regulate genes associated with melanogenesis and senescence bypass. Our results provide key insights into further mechanisms by which melanocytes with reduced MC1R signaling may regulate pigmentation and offer new candidates of study toward understanding how individuals with the RHC phenotype are predisposed to melanoma.

Epidermal melanocytes are continuously exposed to sunlight-induced reactive oxygen species (ROS) and oxidative stress generated during the synthesis of melanin. Therefore, they have developed mechanisms that maintain normal redox homeostasis. Cytoglobin (CYGB), a ubiquitously expressed intracellular iron hexacoordinated globin, exhibits antioxidant activity and regulates the redox state of mammalian cells through its activities as peroxidase and nitric oxide (NO) dioxygenase. We postulated that CYGB functions in the melanogenic process as a regulator that maintains oxidative stress within a physiological level. This was examined by characterizing normal human melanocytes with the knockdown (KD) of CYGB using morphological and molecular biological criteria. CYGB-KD cells were larger, had more dendrites, and generated more melanin granules in the advanced stages of melanogenesis than control cells. The expression levels of major melanogenesis-associated genes and proteins were higher in CYGB-KD melanocytes than in wild type (WT) cells. As expected, CYGB-KD melanocytes generated more ROS and NO than WT cells. In conclusion, CYGB physiologically contributes to maintaining redox homeostasis in the melanogenic activity of normal melanocytes by controlling the intracellular levels of ROS and NO.

Dear Colleagues,

It is with great enthusiasm that we look forward to welcoming you to Philadelphia to celebrate a milestone for the melanoma research community: the 20th Anniversary of the Society for Melanoma Research (SMR). The SMR was established in 2003 during the First International Melanoma Research Congress in Philadelphia. Meenhard Herlyn and Kate O'Neill were the driving force behind the inaugural SMR congress. Kate O'Neill wanted to honor the memory of her sister Noreen, who sadly lost her battle with melanoma. Four years earlier, Kate, Noreen, and Meenhard came together to establish the Noreen O'Neill Foundation for Melanoma Research, which served as the sponsor for the first SMR congress. They jointly envisioned a global community of basic scientists and clinicians sharing their expertise to combat one of the most challenging and deadly forms of cancer. Over the years this vision has become a reality, and a united community with almost 700 members has emerged. The SMR Congress brings together clinicians and scientists from diverse backgrounds to openly share their insights and latest research, and foster collective efforts aimed at battling melanoma.

The SMR has fostered numerous productive collaborations and nurtured the growth of rising talents. By promoting mentorship, exchange of knowledge and resources, and open discussions within the society's annual meetings, the SMR has supported the career of both junior and established researchers, as well as inspired the next generation of melanoma scientists.

In the past 20 years, groundbreaking discoveries and novel therapeutic approaches have shaped the landscape of melanoma treatment. From decoding the complexities of melanoma genetics, unraveling the intricate interactions within the tumor microenvironment, to developing immunotherapies that have revolutionized the treatment of melanoma, the collective efforts of the SMR community have brought us closer to conquering this challenging disease.

To mark the SMR's 20th Anniversary, some of our colleagues reflect on the past two decades, revisiting pivotal moments, landmark discoveries, and the evolution of our society. In this special issue of PCMR, the contributing authors will take us through a journey, tracing the progress of the field under the SMR umbrella.

We sincerely thank our colleagues who have contributed to this special issue, and those who have been part of this journey—researchers, clinicians, trainees, patients, and advocates. The progress made is tangible proof of the power of collaboration, which has placed the melanoma field at the forefront of cancer research uncovering a therapeutic armamentarium that has revolutionized the clinical management of melanoma.

We invite you to join us in Philadelphia to celebrate the accomplishments of the field and the many melanoma researchers who have dedicated their careers to investigating and combating this challenging disease. Here

It has been an honor and privilege to serve as Editor-in-Chief of Pigment Cell & Melanoma Research. This is a unique journal in many respects. It is the official journal of two scientific societies. Established first as Pigment Cell Research under the auspices of the Federation of Pigment Cell Societies, later became Pigment Cell & Melanoma Research by welcoming Society for Melanoma Research to be equal partner. With this merger, the scope of manuscripts now published span the widest range of topics that include chemistry of melanin, vertebrate pigmentation, and pigmentary diseases to melanoma biology and clinical trials. I enjoyed the front row view of this expansive landscape and made every effort to make each issue reflect the scope of the journal.

I have many individuals to thank for making it a worthwhile journey. Foremost, the Associate Editors, who often shouldered equal burden, colleagues, who stepped up every time they were asked to review manuscripts, and the journal staff at Wiley, who supported the workflow. I will miss the opportunity and the privilege of being the first to glimpse research coming out from laboratories across the world. I will miss the opportunity to read the insightful reviews from researchers I hold in high esteem.

Six years ago, when I accepted to serve as Editor-in-Chief of this journal, there was some unspoken skepticism about the viability of the journal in its current form in the fast-changing landscape of journal publishing. As an optimist, I brushed aside such skepticism. Even after 6 years in the trenches, including the difficult period of COVID-19 pandemic, I remain optimistic about the future of this unique journal. There are and will be many challenges to overcome. A journal is only as good as the quality of manuscripts it receives and the peer reviews of those manuscripts. Therefore, it is my sincere hope that the members of the pigment cell and melanoma community, bound together by our interest in this fascinating entity we call “melanocyte”, choose this journal as their first choice to submit and publish their best work and be ready and willing to serve as reviewers. More than anything else, this will be a true test of the commitment of members of this community to the success of this journal. As a member of both pigment cell and melanoma societies, I commit to continue to do my part.

Primary central nervous system (CNS) melanoma is an extremely rare condition, with an incidence rate of 0.01 per 100,000 individuals per year. Despite its rarity, the etiology and pathogenesis of this disease are not yet fully understood. Primary CNS melanoma exhibits highly aggressive biological behavior and presents clinically in a distinct manner from other types of melanomas. It can develop at any age, predominantly affecting the meninges as the primary site, with clinical symptoms varying depending on the neoplasm’s location. Due to the lack of specificity in its presentation and the challenging nature of imaging diagnosis, distinguishing primary CNS melanoma from other CNS diseases. The combination of challenges in early detection, heightened tumor aggressiveness, and the obscured location of its origin contribute to an unfavorable prognostic outcome. Furthermore, there has been currently no consensus on a standardized treatment approach for primary CNS melanoma. Despite recent advancements in targeted therapy and immunotherapy for CNS melanoma, patients with primary CNS melanoma have limited treatment options due to their inadequate response to these therapies. Here, we provided a comprehensive summary of the epidemiology, clinical features, molecular pathological manifestations, and available diagnostic and therapeutic approaches of primary CNS melanoma. Additionally, we proposed potential therapeutic strategies for it.

MFSD12 functions as a transmembrane protein required for import of cysteine into melanosomes and lysosomes. The MFSD12 locus has been associated with phenotypic variation in skin color across African, Latin American, and East Asian populations. The frequency of a particular MFSD12 coding variant, rs2240751 (MAF = 0.08), has been reported to correlate with solar radiation and occur at highest frequency in Peruvian (PEL MAF = 0.48) and Han Chinese (CHB MAF = 0.40) populations, suggesting it could be causative for associated phenotypic variation in skin color. We have generated a mouse knock-in allele, Mfsd12^Y182H, to model the human missense p.Tyr182His human variant. We demonstrate that the variant transcript is stably expressed and that agouti mice homozygote for the variant allele are viable with an altered coat color. This in vivo data confirms that the MFSD12 p.Tyr182His variant functions as a hypomorphic allele sufficient to alter mammalian pigmentation.

The Society for Melanoma Research (SMR) was created 20 years ago and has unequivocally contributed to the vast progress of the field, particularly for the treatment of melanoma patients with metastatic disease by facilitating synergistic collaborations between clinicians, researchers at the bench, and industry. In commemoration of the 20th anniversary of the first SMR International Congress (held in 2003 in Philadelphia), we look to the future by highlighting the perspectives of the next generation of rising stars, medical, and graduate students across six continents.